Bush Proposes $2.8 Billion Increase For NIH In FY2002, Vows $4.1B Next Year.
ACOR Opens Cancer-pain.org
Connie Mack Joins Washington Office Of Shaw Pittman.
Richard Wood, ICRF, Accepts Appointment At Pittsburgh.
Cancer Groups In Campaign To Draft Pazdur For FDA.
NCI Seeks 150 Advocates For Advice On Plans, Policies.
“Harm-Reduction” Products No Proven, IOM Report Says.
MGI Pharma’s Irofulven In Phase III Trial Vs. 5-FU For Advanced Pancreatic Cancer.
FDA Approves Two PSA Tests By roche; Onconase Gets EU Orphan Designation.
Ilex Oncology Buys Symphar, Controls Drug For Bone Mets.
Response Oncology Sells Practice Back To Physicians.
EntreMed Issued U.S. Patent For Active Parts Of Endostatin.
Trending Stories
- What will Trump’s return to the White House mean for oncology?
“Our work just got a lot more difficult.” - Trump 2016: A look back at the 45th president’s impact on oncology
- A study measures the long-term downside of prostate cancer screening
A paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment - At an uncertain time for cancer research and public health, Wayne Frederick steps in as interim CEO at ACS
- GRAIL’s woes raise questions about the prospects of MCDs and standards for their evaluation
- Long-term risks from prostate cancer treatment detailed in new report